安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Tyra Biosciences Pipeline Targets
Tyra Biosciences Pipeline Targets We have built a robust pipeline that leverages our rapid structure-based design process and unique insights into kinase family structures gained through internally derived co-crystal structures
- Our People | Tyra Biosciences
Sarah Honig joined TYRA in July of 2022 as our Vice President, Corporate Development and Strategy Prior to joining TYRA, Sarah was the Chief of Staff at Allogene Therapeutics, where she drove corporate and portfolio strategy, governance, and operations since the inception of the company
- Tyra Biosciences | Next-Generation Precision Medicines
I would like to learn more about Tyra's clinical studies for skeletal dysplasia and urologic cancers *
- Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase . . .
TYRA-300 is a potential first-in-class, investigational, oral, FGFR3-selective inhibitor designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4 TYRA-300 is also being evaluated for metastatic urothelial cancer in the ongoing SURF301 study, where interim clinical proof-of-concept data were recently reported at the ENA 2024 meeting
- Patients | Tyra Biosciences
Dabogratinib (Formerly TYRA-300) SURF303 is an open-label Phase 2 clinical study evaluating the efficacy and safety of dabogratinib, an oral, investigational FGFR3-selective inhibitor, in participants with LG-UTUC The study will enroll up to 130 participants at multiple sites primarily in the United States
- Surf302 | Tyra Biosciences
We are working to advance SURF302 our clinical study of dabogratinib for IR NMIBC Please complete this form to receive updates
- Tyra Biosciences Reports First Quarter 2026 Financial Results and . . .
CARLSBAD, Calif , May 13, 2026 PRNewswire -- Tyra Biosciences, Inc (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the first quarter ended March 31, 2026, and highlighted recent corporate progress
- P0141 A Phase 2A B, Multicenter, Open-Label Study Evaluating the . . .
A Phase 2A B, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low-Grade Upper Tract Urothelial Carcinoma (SURF303) Surena F Matin,1 Gautam Jayram,2 Laura Bukavina,3 Xin Huang,4 Viraj Degaonkar,4 Dinesh Ganapathy,4 Erik Goluboff,4 Morgan Rouprêt5
|
|
|